ROCKET-AF
2011
Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and embolism in AF
In 14,264 patients with non-valvular AF at moderate-high stroke risk, rivaroxaban was non-inferior to warfarin for stroke or systemic embolism, with less intracranial bleeding.
Result
Primary endpoint: Stroke or systemic embolism
1.7 %/yr vs 2.2 %/yr. ICH 0.5 % vs 0.7 %.
- Subtopic
- Anticoagulation
- Design
- Double-blind, double-dummy RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 AFACC/AHA 2023 AF
- Source
- Patel MR, et al. N Engl J Med. 2011;365(10):883-891.doi 10.1056/NEJMoa1009638
Discussion & critique
Warfarin TTR ~ 55 %, low by modern standards; argued to inflate rivaroxaban performance. Once-daily dosing favours adherence.